Surgery May Improve Survival in de Novo Metastatic Breast Cancer

For some women diagnosed with metastatic breast cancer, a more aggressive approach to treating the primary tumor – surgical removal – may be linked to improved survival. This finding, emerging from a complex body of research, challenges the traditional view of metastatic breast cancer as solely a systemic disease managed with therapies targeting the entire body.

Understanding Metastatic Breast Cancer and the Role of Local Therapy

Breast cancer is considered metastatic when it has spread from the original site in the breast to other parts of the body, such as the bones, lungs, liver, or brain. Metastatic breast cancer, also known as stage IV breast cancer, is a systemic disease, meaning it affects the whole body. Traditionally, treatment has focused on systemic therapies – chemotherapy, hormone therapy, targeted therapy, and immunotherapy – designed to reach cancer cells wherever they may be. However, the question of whether to also address the primary tumor locally, through surgery or radiation, has been a subject of ongoing debate.

The conventional wisdom has long held that, in the presence of distant metastases, the primary tumor is less critical and that focusing on systemic treatment is the priority. However, recent research suggests that, in carefully selected patients, local therapy might offer a benefit. This is particularly relevant for women with de novo metastatic breast cancer – meaning the cancer was already metastatic at the time of initial diagnosis.

Conflicting Results and the Challenge of Researching Local Therapy

The evidence surrounding surgical resection of the primary tumor in metastatic breast cancer is not straightforward. A review published in 2022 highlights that four prospective randomized trials and numerous retrospective studies have investigated this question, yielding conflicting results. The challenge lies in the inherent difficulties of conducting research in this area. Retrospective studies, where researchers look back at past patient data, are prone to selection bias. Which means that the patients who receive surgery may differ systematically from those who do not, making it difficult to isolate the effect of the surgery itself.

For example, patients who are generally healthier and have fewer symptoms might be more likely to undergo surgery. This could lead to an overestimation of the surgery’s benefit, as these patients might have done well regardless. Randomized controlled trials, considered the gold standard in medical research, are difficult to conduct in this setting due to ethical considerations and the complexity of patient selection.

Surgical Options and Considerations in the Metastatic Setting

The type of surgery considered for metastatic breast cancer can vary. Medscape reports that surgical management options have evolved over the past decade. It may involve removing the entire breast (mastectomy) or just the tumor and surrounding tissue (lumpectomy). Axillary lymph node dissection, a procedure to remove lymph nodes in the armpit, may also be performed for staging purposes, providing information about the extent of the cancer’s spread. However, the primary goal of surgery in this context is generally palliative – to relieve symptoms and improve quality of life – rather than curative.

surgical resection of distant metastases, such as those in the lungs or liver, is also being investigated. However, the benefit of this approach remains controversial, again due to the challenges of selection bias in retrospective studies.

What Does This Mean for Patients?

The current understanding is that local therapy for metastatic breast cancer is generally palliative. However, the possibility of benefit in select patients, particularly those with de novo metastatic disease and potentially those with a limited number of metastases (sometimes referred to as oligometastasis), warrants further investigation. It’s crucial to emphasize that these are complex decisions that must be made on a case-by-case basis, in close consultation with a multidisciplinary team of healthcare professionals, including surgeons, medical oncologists, and radiation oncologists.

Patients should not interpret this information as a recommendation to undergo surgery. Instead, it highlights the evolving landscape of metastatic breast cancer treatment and the importance of discussing all available options with their doctors. The decision to pursue local therapy should be based on a careful assessment of the individual patient’s overall health, the extent of their disease, and their personal preferences.

The Ongoing Research and Future Directions

Research into the role of local therapy in metastatic breast cancer is ongoing. Clinical trials are continuing to investigate the benefit of surgical resection of primary tumors and distant metastases. Future research will likely focus on identifying biomarkers – measurable characteristics of the cancer – that can help predict which patients are most likely to benefit from local therapy. This could lead to a more personalized approach to treatment, where local therapy is reserved for those patients who are most likely to experience a positive outcome.

The field is also exploring the potential of combining local therapy with systemic therapies in novel ways. For example, researchers are investigating whether surgery can enhance the effectiveness of immunotherapy or targeted therapy.

What comes next: The ongoing evaluation of clinical trial data and the development of predictive biomarkers will be crucial in refining treatment strategies for metastatic breast cancer. Patients are encouraged to discuss participation in clinical trials with their healthcare providers as a way to contribute to advancing knowledge in this area.